Mechanism
Lean mass preservation in incretin therapy
When body weight falls, some lean mass is normally lost alongside fat. The clinical question is whether the proportion of lean-mass loss with incretin therapy is greater than with comparable diet-based weight loss, and how to support muscle and bone during therapy.
Plain-English explanation
When body weight falls, some lean mass is normally lost alongside fat. The clinical question is whether the proportion of lean-mass loss with incretin therapy is greater than with comparable diet-based weight loss, and how to support muscle and bone during therapy.
Research-level explanation
DXA substudies show that lean-mass loss in incretin therapy is broadly in line with diet-based weight loss of similar magnitude. The implications for sarcopenic obesity, older adults and post-treatment recovery are an active research area.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| Incretin therapy melts muscle. | Lean-mass loss with weight reduction is expected; the question is proportion and clinical significance, not whether it occurs. Adequate protein intake and resistance activity are typically advised during therapy. |
Safety relevance
Lean-mass and nutritional safety monitoring is increasingly part of UK specialist weight-management practice.
- Substudy DXA data do not always generalise to older or sarcopenic populations.
Related peptide profiles
Related trials
Related conditions
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site